Johnson & Johnson Projects Double-Digit Growth Despite 62% Drop in Stelara Sales; Investors Warned Not to Ignore Warning Signs

Core Event:Johnson & JohnsonCore Drug Stelara’s Sales Drop 62% Year-on-Year in Q1 2026, Sparking Market Debate on the Sustainability of Future Growth; Current Market Focus Is on Whether Johnson & Johnson’s Other Businesses Can Fill the Revenue Gap Left by Stelara.

Key Data:

Core Market Divergence Between Bulls and Bears: If new businesses can rapidly fill Stada's revenue gap, the current earnings impact on Stada will be a one-time event; otherwise, it signals the beginning of a long-term, industry-wide reset.

Key Follow-up Points:

The translated content is provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; relevant information shall be subject to actual announcements. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express